February 10, 2021

Cardio-Renal Complications of Type 2 Diabetes: The Link Between Renal and Cardiovascular Disease

April 7, 2021

Impact of COVID-19 and New Treatment Approaches

Registration coming soon

June 9, 2021

2021 Guideline Updates and Implications to Patient Care

Registration coming soon

September 8, 2021

Bridging the Gap: Disparities in Heart Failure Associated with T2D: An Opportunity to Improve Care in the African-American Community

Registration coming soon

November 10, 2021

Overview of Therapeutic Options in the Treatment of NASH/NAFLD

Registration coming soon

Type 2 Diabetes and Kidney Disease: Patient engagement and how to manage chronic conditions

Originally presented on October 21, 2020 by Ted Okerson, MD, FACP, FACE, FTOS; Kerry Cooper, MD; Susan Guzman, PhD; and Donna Stevens, DNP, FNP-BC,
BC-ADM, CDCES

In this panel discussion, understand key points of clinical intervention, as well as how to engage people with diabetes in discussions about chronic conditions early in development of disease, and how to encourage adopting healthy behaviors.

Upon completion of this activity, participants will be able to:

1. Understand key points of clinical intervention
2. Engage people with diabetes in discussions about chronic conditions early in development of disease
3. Encourage adopting healthy behaviors

SGLT-2 Inhibitors: A Dynamic and Evolving Therapeutic Option

Originally presented on December 2, 2020 by Paul Tomasic, MD, MS, FACP, FACE and Davida F. Kruger, MSN, APN-BC, BC-ADM

This webinar will go over how SGLT-2 inhibition impacts the physiology of the kidney and heart. Understand the clinical effects on glycemia, MACE, hHF, and renal endpoints in diabetes, as well as the evolving landscape and use of these agents in patients without diabetes.

Upon completion of this activity, participants will be able to:

1. Describe the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the physiology of cardiorenal disease
2. Discuss the clinical effects of SGLT2 inhibition on glycemia, major adverse cardiovascular events, hospitalization for heart failure, and renal endpoints in diabetes
3. Summarize the evolving landscape of evidence related to SGLT2 inhibition in patients without diabetes